Estrogen deprivation therapies, such as selective estrogen receptor modulators (SERMs), have demonstrated promise in cancer treatment by stimulating NK cell and CD8+ T cell activation, particularly in peripheral blood from triple-negative breast cancer (TNBC) patients 170. This evidence concerns the gene CD8A and cancer.